Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | DHFR | P00374 | 6/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | ADCY10 | Q96PN6 | 2/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | GPR68 | Q15743 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4114237 | 0.83 | MAP4K4 (0.41) | ABL1DHFRPDE2APDE10AMAP4K4 | |
| SCHEMBL4107330 | 0.83 | PDE2A (0.39) | DHFRPDE2APDE10AMAP4K4TLR8 | |
| SCHEMBL4110095 | 0.82 | MAP4K4 (0.46) | MPODHFRMAP4K4HTR1AGPR68 | |
| SCHEMBL4106793 | 0.82 | MPO (0.44) | MPODHFRMAP4K4TLR8TLR7 | |
| SCHEMBL4097721 | 0.79 | MAP4K4 (0.43) | MPODHFRMAP4K4TLR8TLR7 | |
| SCHEMBL4097752 | 0.77 | MPO (0.42) | MPODHFRADCY10MAP4K4TLR8 | |
| SCHEMBL4114713 | 0.75 | MPO (0.43) | MPODHFRADCY10MAP4K4TLR8 | |
| SCHEMBL4107954 | 0.75 | MPO (0.47) | MPODHFRMAP4K4TLR8TLR7 | |
| SCHEMBL4110107 | 0.75 | MPO (0.44) | MPODHFRTLR8TLR7 | |
| SCHEMBL4115070 | 0.74 | MPO (0.51) | MPODHFRADCY10TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253696-A1 | SUBSTITUTED PYRIDO(3,2-D) PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2009-10-08 | — | — | US | claimed |
| WO-2008009076-A2 | SUBSTITUTED PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | claimed |
| US-8338435-B2 | Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections | GILEAD SCIENCES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20090253696-A1 | SUBSTITUTED PYRIDO(3,2-D) PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2009-10-08 | — | — | US | disclosed |
| WO-2008009076-A2 | SUBSTITUTED PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253696-A1 | SUBSTITUTED PYRIDO(3,2-D) PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | PNPO, PNP, DPYD | MPO 2952/4885ABL1 766/4885DHFR 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.